Erchonia Asia, the global provider in low level laser healthcare applications, has launched Zerona body-contouring laser in South East Asia’s SAARC, which will be exclusively marketed and sold by the company throughout the region.
The new expansion coincides with the recent US Food and Drug Administration (FDA) approval of the Zerona Laser as a non-invasive, painless treatment that guarantees the removal of fat without affecting fat cell.
Erchonia Asia CEO Anoop Chaturvedi said that they are certain Zerona’s research, development and proven efficacy combined with their local market knowledge will ensure the tremendous success of this launch and the recent FDA approval for Zerona has triggered expansion opportunities and opened up an entire market for developing countries.
Erchonia claims that Zerona is the only device on the market to prove its efficacy through a double blind, multi-site, placebo controlled study, and is the only non-invasive procedure that guarantees an average of three inches lost in as little as two weeks.
In pilot studies, Zerona has been shown to increase sensitivity to the hunger-hormone leptin, which decreases patients’ appetite, helping them modify their diet and portion choices going forward.